Detection of Early-stage Lung Cancer Based on Liquid Biopsy of Peripheral Blood: a Prospective Study

Peking University People's Hospital1 site in 1 country467 target enrollmentFebruary 19, 2021

ConditionsLung Cancer

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Lung Cancer
Sponsor: Peking University People's Hospital
Enrollment: 467
Locations: 1
Primary Endpoint: Accuracy of the multi-omics early-stage lung cancer diagnosis model
Status: Recruiting
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to develop a lung cancer diagnosis tool using a multi-omics approach based on liquid biopsy.

Detailed Description

After being informed about the study and potential risks, all patients giving written informed consent will undergo a screening process to determine eligibility of study entry. Peripheral blood, tissue sample and imaging examinations of eligible patients will be collected for further analysis. Data collected will be used to develop a multi-omics lung cancer diagnosis model.

Registry

clinicaltrials.gov

Start Date

February 19, 2021

End Date

December 31, 2024

Last Updated

5 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Peking University People's Hospital

Responsible Party

Principal Investigator

Jun Wang

Professor

Peking University People's Hospital

Eligibility Criteria

Inclusion Criteria

•Signed informed consent
•Male or female, age equal to or greater than 40 years old and less than 75 years old
•Blood sample was collected before surgery for the detection of cfDNA methylation and other biomarkers
•Lung cancer patients diagnosed for the first time within 42 days before blood sampling without any anti-tumor treatment; or patients who are highly suspected of lung cancer through imaging evaluation or other routine clinical diagnosis and confirmed by tissue biopsy or surgical specimens within 42 days after blood sampling
•The subject has not received any local or systemic anti-tumor therapy before blood collection, including (not limited to) any surgery, local or systemic radiotherapy and chemotherapy, targeted therapy (including anti-angiogenesis), immunotherapy, cancer vaccines and hormone therapy, etc.

Exclusion Criteria

•Unable to obtain sufficient and qualified blood samples
•Female subjects who are pregnant or breastfeeding
•Patients who have received organ transplantation or non-autologous bone marrow or stem cell transplantation
•Patients who have received blood transfusion within 7 days before blood sampling
•Patients who have received anti-infection treatment within 14 days before blood collection
•Patients who have receiving anti-tumor drugs for other diseases within 30 days before blood collection, such as methotrexate, cyclophosphamide, mercaptopurine, chlorambucil, tamoxifen, etc.
•Patients who suffered from other malignant tumors or multiple primary tumors at the same time
•Pathological confirmed benign lesions by tissue biopsy or surgery
•Insufficient sample for a confirmed pathological diagnosis
•Lung cancer patients with ground glass nodules on CT imaging.

Outcomes

Primary Outcomes

Accuracy of the multi-omics early-stage lung cancer diagnosis model

Time Frame: through study completion, an average of 1.5 year

Sensitivity and specificity of the multi-omics early-stage lung cancer diagnosis model

Secondary Outcomes

Accuracy of diagnostic models established separately from multi-omics data(through study completion, an average of 1.5 year)
Relationship between multi-omics data(through study completion, an average of 1.5 year)